Abstract
The actions of a series of derivatives of 3-aminopropyl-phosphinic acid as baclofen agonists and antagonists have been examined on the synaptic excitation of neurones by impulses in primary afferent fibres in the lumbar spinal cords of pentobarbitone-anaesthetised cats and rats. Both the pre-and postsynaptic inhibitory actions of microelectrophoretic (-)-baclofen were reduced by similarly administered CGP 35 348, 36 742, 46 381, 52 432, 54 626 and 55 845, the latter being the most potent antagonist. None of these antagonists either decreased or increased the excitability of spinal neurones, and the inhibitory action of GABA was reduced only by local concentrations of antagonists which also reduced the action of piperidine-4-sulphonic acid, a GABAA agonist. Although the weak inhibitory effect of 3-aminopropylphosphinic acid in both the rat and the cat was not reduced by these baclofen antagonists, the pre-and postsynaptic inhibitory effects of 3-aminopropyl-methyl-osphinic acid (CGP 35 024), which was more potent than (-)-baclofen, were reduced by the antagonists. Like (-)-baclofen, CGP 35 024 was relatively ineffective in reducing transmitter release in the cord from the terminals of excitatory spinal interneurones, the terminals of excitatory tracts in the dorsolateral funiculus and the cholinergic terminals of motor axon collaterals. In both rat and cat cords, receptors for (-)-baclofen could not be demonstrated to be activated by microelectrophoretic GABA, possibly because of the predominantly dendritic location of GABAB receptors. Spinal pre-and postsynaptic baclofen receptors appeared to be pharmacologically similar but differed from those in the higher central nervous system of the rat, where 3-aminopropylphosphinic acid has been reported to be an effective baclofen agonist. The compounds tested, particularly CGP 55 845 and 46 381, will be of use in further investigations of the physiological relevance of baclofen receptors at central synapses where GABA may be the transmitter.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andre P, Ferrat T, Steinman M, Olpe H-R (1992) Increased acetylcholine and quisqualate responsiveness after blockade of GABAB receptors. Eur J Pharmacol 218:137–143
Beattie DT, Curtis DR, Debaert M, Vaccher C, Berthelot P (1989) Baclofen antagonism by 4-ammo-3-[5-methoxybenzo(b) furan-2-yl] butanoic acid in the cat spinal cord. Neurosci Lett 100:292–294
Billard JM, Vigot R, Batini C (1993) GABA, THIP and baclofen inhibition of Purkinje cells and cerebellar nuclei neurons. Neurosci Res 16:65–69
Bittiger H, Reymann N, Hall R, Kane P (1988) A new potent and selective radioligand for GABAB receptors. Eur J Neurosci [Suppl] 1:60
Bittiger H, Bernasconi R, Froestl W, Hall R, Jaekel J, Klebs K, Krueger L, Mickel SJ, Mondadori C, Olpe H-R, Pfannkuch F, Pozza M, Probst A, Van Riezen H, Schmutz M, Schuetz H, Steinmann MW, Vassout A, Waldmeier P, Bieck P, Farger G, Gleiter C, Schmidt EK, Marescaux C (1992) GABAB antagonists: potential new drugs. Pharmacol Commun 2:70–74
Bowery NG, Pratt GD (1992) GABAB receptors as targets for drug action. Drug Res 42:215–223
Bowery NG, Hill DR, Hudson AL (1983) Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes. Br J Pharmacol 78:191–206
Bowery NG, Bittiger H, Olpe H-R (1990) GABAB receptors in mammalian function. Wiley & Sons, Chichester
Brugger F (1992) GABAB receptors in the spinal cord. Pharmacol Commun 2:127–130
Brugger F, Wicki U, Olpe H-R, Froestl W, Mickel S (1993) The action of new potent GABAB receptor antagonists in the hemisected spinal cord preparation of the rat. Eur J Pharmacol 235:153–155
Curtis DR (1976) The use of transmitter antagonists in microelectrophoretic investigations of central transmission. In: Bradley PB, Dhawan BN (eds) Drugs and central synaptic transmission. MacMillan, London, pp 7–35
Curtis DR, Lacey G (1994) GABA-b receptor-mediated spinal inhibition. Neuroreport 5:540–542
Curtis DR, Lodge D (1982) The depolarization of feline ventral horn group Ia spinal afferent terminations by GABA. Exp Brain Res 46:215–233
Curtis DR, Malik R (1985) The differential effects of baclofen on segmentai and descending excitation of spinal interneurones in the cat. Exp Brain Res 58:333–337
Curtis DR, Phillis JW, Watkins JC (1959) The depression of spinal neurones by γ-amino-n-butyric acid and β -alanine. J Physiol (Lond) 146:185–203
Curtis DR, Duggan AW, Felix D, Johnston GAR (1971a) Bicuculline, an antagonist of GABA and synaptic inhibition in the spinal cord. Brain Res 32:69–96
Curtis DR, Duggan AW, Johnston GAR (1971b) The specificity of strychnine as a glycine antagonist in the mammalian spinal cord. Exp Brain Res 12:547–565
Curtis DR, Game CJA, Johnston GAR, McCulloch RM (1974) Central effects of β-(p-chlorophenyl)-γ-aminobutyric acid. Brain Res 70:493–499
Curtis DR, Lodge D, Bornstein JC, Peet MJ (1981) Selective effects of (-)-baclofen on spinal synaptic transmission in the cat. Exp Brain Res 42:158–170
Curtis DR, Gynther BD, Beattie DT, Kerr DIB, Prager RH (1988) Baclofen antagonism by 2-hydroxy-saclofen in the cat spinal cord. Neurosci Lett 92:97–101
Davies J (1981) Selective depression of synaptic excitation in cat spinal neurones by baclofen: an iontophoretic study. Br J Pharmacol 72:373–384
Dutar P, Nicoll RA (1988) A physiological role for GABAB receptors in the central nervous system. Nature 332:156–158
Eccles JC, Fatt P, Koketsu K (1954) Cholinergic and inhibitory synapses in a pathway from motor-axon collaterals to motoneurones. J Physiol (Lond) 126:524–562
Edwards FR, Harrison PJ, Jack JJB, Kullmann DM (1989) Reduction by baclofen of monosynaptic EPSPs in lumbosacral motoneurones of the anaesthetised cat. J Physiol (Lond) 416:539–556
Faigle JW, Keberle H (1972) The metabolism and pharmacokinetics of Lioresal. In: Birkmayer W (ed) Spasticity — a topical survey. Huber, Berne, pp 94–100
Fox S, Krnjevic K, Morris ME, Puil E, Werman R (1978) Action of baclofen on mammalian synaptic transmission. Neuroscience 3:495–515
Froestl W, Mickel SJ, Von Sprecher G, Bittiger H, Olpe H-R (1992) Chemistry of new GABAB antagonists. Pharmacol Commun 2:52–56
Fromm GH, Shibuya T, Nakata M, Terrence CF (1990) Effects of d-baclofen and l-baclofen on the trigeminal nucleus. Neuropharmacology 29:249–254
Fromm GH, Sato K, Nakata M (1992) The action of GABAB antagonists in the trigeminal nucleus of the rat. Neuropharmacology 31:475–480
Hill DR, Bowery NG (1981) 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABAB sites in rat brain. Nature 290:149–152
Huston E, Scott RH, Dolphin AC (1990) A comparison of the effect of calcium channel ligands and GABAB agonists and antagonists on transmitter release and somatic calcium channel currents in cultured neurons. Neuroscience 38:721–729
Jarolimek W, Demmelhuber J, Bijak M, Misgeld U (1993) CGP 55845A blocks baclofen, γ-aminobutyric acid and inhibitory postsynaptic potassium currents in guinea pig CA3 neurons. Neurosci Lett 154:31–34
Johnston GAR, Beart PM, Curtis DR, Game CJA, McCulloch RM, Maclachlan RM (1972) Bicuculline methochloride as a GABA antagonist. Nature 240:219–220
Kerr DIB, Ong J, Prager R H, Gynther BD, Curtis DR (1987) Phaclofen: a peripheral and central baclofen antagonist. Brain Res 405:150–154
Knutsson E, Lindblom U, Martensson A (1974) Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 23:473–484
Krogsgaard-Larsen P, Falch E, Schousboe A, Curtis DR, Lodge D (1980) Piperidine-4-sulphonic acid, a new specific GABA agonist. J Neurochem 34:756–759
Lacey G, Curtis DR (1993) Baclofen antagonism by CGP 35 348 in the spinal cord in vivo (abstract). Proc Aust Neurosci Soc 4:52
Lingenhöhl K, Olpe HR (1993) Blockade of the late inhibitory postsynaptic potential in vivo by the GABAB blocker CGP 46 381. Pharmacol Commun 3:49–54
Lovinger, DM, Harrison NL, Lambert NA (1992) The actions of 3-aminopropanephosphinic acid at GABAB receptors in rat hippocampus. Eur J Pharmacol 211:337–341
Olpe H-R, Karlsson G, Pozza MF, Brugger F, Steinmann M, Van Riezen H, Fagg G, Hall RG, Frostl W, Bittiger H (1990) CGP 35 348: a centrally active blocker of GABAB receptors. Eur J Pharmacol 187:27–38
Olpe H-R, Ferrat T, Wörner W, Andre P, Steinmann MW (1992) Evidence for a “GABAB tone” in vivo: the effect of CGP 35 348 on long-term potentiation, paired-pulse inhibition and cortical excitability. Pharmacol Commun 2:121
Olpe H-R, Steinmann MW, Ferrat T, Pozza MF, Greiner K, Brugger F, Froestl W, Mickel SJ, Bittiger H (1993) The actions of orally active GABAB receptor antagonists on GABAergic transmission in vivo and in vitro. Eur J Pharmacol 233:179–186
Ong J, Harrison NL, Hall RG, Barker JL, Johnston GAR, Kerr DIB (1990) 3-Aminopropanephosphinic acid is a potent agonist at peripheral and central presynaptic GABAB receptors. Brain Res 526:138–142
Penn RD (1992) Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 77:236–240
Pierrefiche O, Foutz AS, Denavit-Saubie M (1993) Effects of GABAB receptor agonists and antagonists on the bulbar respiratory network in cat. Brain Res 605:77–84
Pratt GD, Knott C, Davey R, Bowery NG (1989) Characterisation of 3-aminopropylphosphinic acid (3-APPA) as a GABAB agonist in rat brain tissue. Br J Pharmacol 96:141P
Seabrook GR, Howson W, Lacey MG (1990) Electrophysiological characterization of potent agonists and antagonists at pre-and postsynaptic GABAB receptors on neurones in rat brain slices. Br J Pharmacol 101:949–957
Smith CR, LaRocca NG, Giesser BS, Scheinberg LC (1991) Highdose oral baclofen: experience in patients with multiple sclerosis. Neurology 41:1829–1831
Solis JM, Nicoll RA (1992) Pharmacological characterization of GABAB-mediated responses in the CA1 region of the rat hippocampal slice. J Neurosci 12:3466–3472
Terrence CF, Sax M, Fromm GH, Chang C-H, Yoo CS (1983) Effect of baclofen enantiomorphs on the spinal trigeminal nucleus and steric stimilarities of carbamazepine. Pharmacology 27:85–94
Thompson SM, Gähwiler BH (1992) Comparison of the actions of baclofen at pre-and postsynaptic receptors in the rat hippocampus in vitro. J Physiol (Lond) 451:329–345
Turgeon SM, Albin RL (1993) Pharmacology, distribution, cellular localization, and development of GABAB binding in rodent cerebellum. Neuroscience 55:311–323
Young RR, Delwaide PJ (1981) Drug therapy. Spasticity. N Engl J Med 304:96–99
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lacey, G., Curtis, D.R. Phosphinic acid derivatives as baclofen agonists and antagonists in the mammalian spinal cord: an in vivo study. Exp Brain Res 101, 59–72 (1994). https://doi.org/10.1007/BF00243217
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00243217